Company intelligence / Profile preview

Synergy Pharmaceuticals Inc.

New York, New York, USAsynergyphar.com ↗

Ownership: Private
Development stage: Commercial

Overview

Synergy Pharmaceuticals developed and commercialized TRULANCE® (plecanatide), a once-daily oral GC-C agonist approved by the FDA for chronic idiopathic constipation and irritable bowel syndrome with constipation. The company also advanced dolcanatide, another GC-C agonist, into clinical trials for ulcerative colitis. Synergy filed for bankruptcy in late 2018 and its key assets, including TRULANCE, were acquired by Bausch Health in early 2019[1][7].

Therapeutic areas: Gastroenterology
Modalities: Small molecules (GC-C agonists)
Industry: Biotech

Drug pipeline

3 assets

plecanatide

Approved

2 more assets in the full pipeline.

Request access →

Partnerships

Cipher Pharmaceuticals licensed rights to develop/market/sell TRULANCE in Canada[1]

Beyond the preview

Go deeper on Synergy Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synergy Pharmaceuticals Inc..

Explore the full profile